WO2008124000A3 - Thiazole derivatives as androgen receptor modulator compounds - Google Patents

Thiazole derivatives as androgen receptor modulator compounds Download PDF

Info

Publication number
WO2008124000A3
WO2008124000A3 PCT/US2008/004287 US2008004287W WO2008124000A3 WO 2008124000 A3 WO2008124000 A3 WO 2008124000A3 US 2008004287 W US2008004287 W US 2008004287W WO 2008124000 A3 WO2008124000 A3 WO 2008124000A3
Authority
WO
WIPO (PCT)
Prior art keywords
androgen receptor
receptor modulator
thiazole derivatives
modulator compounds
compounds
Prior art date
Application number
PCT/US2008/004287
Other languages
French (fr)
Other versions
WO2008124000A2 (en
Inventor
Lin Zhi
E Adam Kallel
Bao Ngoc Nguyen
Mark E Adams
Yixing Shen
Thomas Lot Stevens Lau
Jyun-Hung Chen
John S Tyhonas
Robert J Ardecky
Todd A Miller
Jon C Loren
Original Assignee
Ligand Pharm Inc
Lin Zhi
E Adam Kallel
Bao Ngoc Nguyen
Mark E Adams
Yixing Shen
Thomas Lot Stevens Lau
Jyun-Hung Chen
John S Tyhonas
Robert J Ardecky
Todd A Miller
Jon C Loren
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ligand Pharm Inc, Lin Zhi, E Adam Kallel, Bao Ngoc Nguyen, Mark E Adams, Yixing Shen, Thomas Lot Stevens Lau, Jyun-Hung Chen, John S Tyhonas, Robert J Ardecky, Todd A Miller, Jon C Loren filed Critical Ligand Pharm Inc
Publication of WO2008124000A2 publication Critical patent/WO2008124000A2/en
Publication of WO2008124000A3 publication Critical patent/WO2008124000A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Provided herein are compounds of formula (I), (II), (III) or (IV) that bind to androgen receptors and/or modulate activity of androgen receptors and/or modulate the amount of androgen receptors and/or reduce the number of androgen receptors in a cell and/or degrade androgen receptors in a cell; and to methods for making and using such compounds. Also provided are compositions containing such compounds and methods for making and using such compositions.
PCT/US2008/004287 2007-04-02 2008-04-01 Thiazole derivatives as androgen receptor modulator compounds WO2008124000A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92165207P 2007-04-02 2007-04-02
US60/921,652 2007-04-02

Publications (2)

Publication Number Publication Date
WO2008124000A2 WO2008124000A2 (en) 2008-10-16
WO2008124000A3 true WO2008124000A3 (en) 2009-04-02

Family

ID=39737137

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/004287 WO2008124000A2 (en) 2007-04-02 2008-04-01 Thiazole derivatives as androgen receptor modulator compounds

Country Status (1)

Country Link
WO (1) WO2008124000A2 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR044519A1 (en) 2003-05-02 2005-09-14 Novartis Ag DERIVATIVES OF PIRIDIN-TIAZOL AMINA AND PIRIMIDIN-TIAZOL AMINA
PE20091523A1 (en) 2007-12-20 2009-10-29 Novartis Ag THIAZOL DERIVATIVES AS INHIBITORS OF THE ENZYME PHOSPHATIDYLINOSITOL 3-KINASE (PI3K)
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
WO2009105214A2 (en) 2008-02-22 2009-08-27 Radius Health, Inc. Selective androgen receptor modulators
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
UA104147C2 (en) 2008-09-10 2014-01-10 Новартис Аг Pyrrolidine dicarboxylic acid derivative and use thereof in the treatment of proliferative diseases
EP2403499B1 (en) 2009-03-02 2019-09-18 StemSynergy Therapeutics, Inc. Methods and compositions for use in treating cancer and reducing wnt mediated effects in a cell
GB0905525D0 (en) * 2009-03-31 2009-05-13 Univ Leiden Compounds and uses
EA201200087A1 (en) 2009-07-02 2012-07-30 Новартис Аг 2-CARBOXAMIDES CYCLOAMINUM CEAMS WHICH ARE PI3K INHIBITORS
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
AR078793A1 (en) 2009-10-27 2011-12-07 Orion Corp DERIVATIVES OF NON-STEROID CARBOXAMIDS AND ACIL HYDRAZONE MODULATORS OF ANDROGENIC RECEPTORS OF SELECTIVE FABRIC (SARM), PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE OF THE SAME IN THE TREATMENT OF PROSTATE CANCER BETWEEN OTHERS
AU2011212813B2 (en) 2010-02-04 2014-10-23 Radius Health, Inc. Selective androgen receptor modulators
JP5825535B2 (en) * 2010-03-17 2015-12-02 タイヴェックス・セラピューティクス・コーポレイションＴａｉｖｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｏｒｐｏｒａｔｉｏｎ Modulators of HEC1 activity and methods therefor
ME02474B (en) 2010-05-12 2017-02-20 Radius Health Inc Therapeutic regimens
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
CA2806766C (en) * 2010-07-28 2017-01-10 Neugen Pharma Inc. Novel amino imidazole compounds selectively suppress oxidative stress induced neurodegeneration
EP2621901B1 (en) 2010-09-28 2015-07-29 Radius Health, Inc Selective androgen receptor modulators
MX360611B (en) * 2011-04-21 2018-11-09 Orion Corp Androgen receptor modulating carboxamides.
US11071736B2 (en) 2011-11-21 2021-07-27 Taivex Therapeutics Corporation Modulators of HEC1 activity and methods therefor
US9951055B2 (en) 2012-10-19 2018-04-24 Massachusetts Institute Of Technology Thiazole-based inhibitors of scavenger receptor BI
WO2014063168A1 (en) 2012-10-19 2014-04-24 The Broad Institute, Inc. Heterocycle-bisamide inhibitors of scavenger receptor bl
US20160046616A1 (en) * 2013-03-15 2016-02-18 The Johns Hopkins University Nrf2 small molecule inhibitors for cancer therapy
MX367554B (en) * 2013-06-05 2019-08-27 C&C Res Lab Heterocyclic derivatives and use thereof.
JP6434968B2 (en) 2013-07-02 2018-12-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Tricyclic pyrido-carboxamide derivatives as ROCK inhibitors
EP3016950B1 (en) 2013-07-02 2017-06-07 Bristol-Myers Squibb Company Tricyclic pyrido-carboxamide derivatives as rock inhibitors
US20150126507A1 (en) * 2013-09-05 2015-05-07 Fate Therapeutics, Inc. Compounds to treat hearing loss
US9682960B2 (en) 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
WO2015129853A1 (en) * 2014-02-27 2015-09-03 東レ株式会社 Cyclic amine derivative and pharmaceutical use thereof
DK3122426T3 (en) 2014-03-28 2023-04-03 Univ Duke Treatment of breast cancer using selective estrogen receptor modulators
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
KR20160066490A (en) * 2014-12-02 2016-06-10 주식회사 씨앤드씨신약연구소 Heterocyclic derivatives and use thereof
WO2016089062A2 (en) 2014-12-02 2016-06-09 C&C Research Laboratories Heterocyclic derivatives and use thereof
ES2578363B1 (en) * 2015-01-22 2017-01-31 Palobiofarma, S.L. A3 adenosine receptor modulators
CN107735085B (en) 2015-04-21 2021-05-14 Gtx公司 Selective Androgen Receptor Degrader (SARD) ligands and methods of use thereof
WO2016172358A1 (en) 2015-04-21 2016-10-27 Gtx, Inc. Selective androgen receptor degrader (sard) ligands and methods of use thereof
US10441570B2 (en) 2015-04-21 2019-10-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) Ligands and methods of use thereof
US10654809B2 (en) 2016-06-10 2020-05-19 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10017471B2 (en) 2015-04-21 2018-07-10 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US9834507B2 (en) 2015-04-21 2017-12-05 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10035763B2 (en) 2015-04-21 2018-07-31 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10093613B2 (en) 2015-04-21 2018-10-09 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10806720B2 (en) 2015-04-21 2020-10-20 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10865184B2 (en) 2015-04-21 2020-12-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
RU2747228C2 (en) 2015-04-29 2021-04-29 Радиус Фармасьютикалз, Инк. Methods for treating cancer
WO2017019772A1 (en) * 2015-07-27 2017-02-02 Sanford Burnham Prebys Medical Discovery Institute Modulators of myocyte lipid accumulation and insulin resistance and methods of use thereof
US11230523B2 (en) 2016-06-10 2022-01-25 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
LT3474841T (en) 2016-06-22 2022-06-10 Ellipses Pharma Ltd Ar+ breast cancer treatment methods
KR101983788B1 (en) * 2016-12-01 2019-05-30 서울대학교산학협력단 Amide derivative compounds, stereoisomer thereof, or pharmaceutically acceptable salts thereof, and pharmaceutical or cosmetic composition for antiaging, antiwrinkle, or wound healing on skin containing the same
PL3565542T3 (en) 2017-01-05 2024-07-29 Radius Pharmaceuticals, Inc. Polymorphic forms of rad1901-2hcl
WO2020010216A1 (en) 2018-07-04 2020-01-09 Radius Pharmaceuticals, Inc. Polymorphic forms of rad 1901-2hcl
CN115989219A (en) * 2020-06-29 2023-04-18 贝凯恩生物医疗技术有限公司 Probenecid compounds for the treatment of inflammasome-mediated pulmonary diseases

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1361220A1 (en) * 2001-01-26 2003-11-12 Shionogi & Co., Ltd. Cyclic compounds having thrombopoietin receptor agonism
WO2004041813A1 (en) * 2002-10-30 2004-05-21 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
WO2004096798A2 (en) * 2003-04-25 2004-11-11 Sanofi-Aventis Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and use of same as chemokine antagonists
WO2005025572A1 (en) * 2003-09-10 2005-03-24 Merck & Co., Inc. 17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators
WO2006116301A1 (en) * 2005-04-22 2006-11-02 The Johns Hopkins University Neuroprotective compounds for treating optic neuropathies

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1361220A1 (en) * 2001-01-26 2003-11-12 Shionogi & Co., Ltd. Cyclic compounds having thrombopoietin receptor agonism
WO2004041813A1 (en) * 2002-10-30 2004-05-21 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
WO2004096798A2 (en) * 2003-04-25 2004-11-11 Sanofi-Aventis Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and use of same as chemokine antagonists
WO2005025572A1 (en) * 2003-09-10 2005-03-24 Merck & Co., Inc. 17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators
WO2006116301A1 (en) * 2005-04-22 2006-11-02 The Johns Hopkins University Neuroprotective compounds for treating optic neuropathies

Also Published As

Publication number Publication date
WO2008124000A2 (en) 2008-10-16

Similar Documents

Publication Publication Date Title
WO2008124000A3 (en) Thiazole derivatives as androgen receptor modulator compounds
WO2007005887A3 (en) Androgen receptor modulator compounds, compositions and uses thereof
WO2009082437A3 (en) Selective androgen receptor modulators (sarms) and uses thereof
WO2006138347A3 (en) Androgen receptor modulator compounds and methods
WO2009078981A3 (en) Ppar-delta ligands and methods of their use
EP2266056A4 (en) Dynamic formulas for spreadsheet cells
WO2011006886A3 (en) Azole derivatives as agricultural fungicides
WO2009020234A3 (en) Pyrrolidin-2 -one derivatives as androgen receptor modulator
ZA201000127B (en) Novel 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors
GB2453304B (en) Hydraulic cements comprising carbonate compound compositions
GEP20125426B (en) Tricyclic compounds and their use as glucocorticoid receptor modulators
TW200800956A (en) 2-Aminopyrimidine derivatives
WO2008064353A3 (en) 7,8-saturated-4,5-epoxy-morphinanium analogs
ZA201108618B (en) Stable topical compositions for 1,2,4-thiadiazole derivatives
EP2201078A4 (en) Improved sealing composition
EP2258668A4 (en) Additive composition for hydraulic compositions
IN2012DN02876A (en)
WO2011149993A3 (en) SUBSTITUTED OCTAHYDROCYCLOPENTA[c]PYRROLES AS CALCIUM CHANNEL MODULATORS
WO2010057088A3 (en) Pyrrolidinyl modulators of nicotinic acetylcholine receptors
WO2007024744A3 (en) Heterocyclic carboxamide compounds as steroid nuclear receptor ligands
HK1115500A1 (en) Isoquinolines as igf-1r inhibitors
WO2011050054A3 (en) Coumarin compounds as receptor modulators with therapeutic utility
WO2007075884A3 (en) Androgen receptor modulator compounds and methods
WO2011084434A3 (en) Aza-ring fused indole and indoline derivatives
EP2313516A4 (en) Compositions and methods for modulating nod-like receptor activity and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08727253

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08727253

Country of ref document: EP

Kind code of ref document: A2